Specifically, the authors examined the status of CD3(+), CD4(+), CD8(+), CD20(+), and CD68(+) cells separately in the tumor center and the invasive front and demonstrated that increased CD3(+) T cell density at the tumor center is associated with a favorable response to neoadjuvant chemotherapy [51]. The gene discussed is CD68; the disease is neoplasm.